Showing 1-10 of 25 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Determining the role of new genes that may be involved in Type 1 Diabetes Pathogenesis | Beth Israel Deaconess Medical Center Inc | Ismail Syed | Cures | 01-June-2024 to 31-October-2025 | $199,999.67 |
| Integration of Slow-Release A1AT-loaded Nanoparticles for Enhanced Cell Therapy in Type 1 Diabetes | Beth Israel Deaconess Medical Center Inc | Giuseppe Pettinato | Cures | 01-October-2024 to 30-September-2025 | $200,000.00 |
| New lipid biomarker to predict early risk for Type 1 diabetes | Beth Israel Deaconess Medical Center Inc | Barbara Kahn | Cures | 01-September-2024 to 31-August-2027 | $899,997.53 |
| A wireless oxygen generating immune protection device to support long term cell transplantation for the treatment of Type I Diabetes | Boston Children's Hospital | Robert Langer | Cures | 01-August-2025 to 31-July-2028 | $2,481,286.98 |
| Engineered Nanobodies to Visualize and Direct Antigen-Specific Tolerance in T1D | Boston Children's Hospital | Novalia Pishesha | Cures | 01-March-2025 to 28-February-2030 | $999,999.00 |
| T1D Global Access Grand Strategy | Clinton Health Access Initiative (CHAI) | Nine Steensma | Mission | 01-August-2024 to 30-September-2025 | $1,179,001.50 |
| Closing the T1D diagnosis gap in Ethiopia, Ghana and Nigeria | Clinton Health Access Initiative (CHAI) | Margaret Prust | Mission | 01-September-2023 to 31-August-2026 | $1,702,076.57 |
| Advanced Oxygen Generator for Oxygenated Cell Capsules | Giner, Inc. | Linda Tempelman | Cures | 01-June-2021 to 31-December-2025 | $448,173.29 |
| Evaluating the dose and toxicity of telaprevir in a rat model of T1D | Joslin Diabetes Center Inc. | Rohit Kulkarni | Cures | 01-June-2022 to 31-December-2025 | $494,000.00 |
| Targeting RNLS for Type 1 Diabetes Therapy | Joslin Diabetes Center Inc. | Peng Yi | Cures | 01-June-2025 to 31-May-2028 | $1,349,997.00 |